SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Boman Kurt) "

Sökning: WFRF:(Boman Kurt)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Rautio, Aslak, et al. (författare)
  • The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events : Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial
  • 2017
  • Ingår i: Diabetes & Vascular Disease Research. - : Sage Publications. - 1479-1641 .- 1752-8984. ; 14:4, s. 345-352
  • Tidskriftsartikel (refereegranskat)abstract
    • Introduction: Fibrinolytic factors, plasminogen activator inhibitor-1, tissue plasminogen activator, tissue plasminogen activator/plasminogen activator-complex and the haemostatic factor von Willebrand factor are known markers of cardiovascular disease. Their plasma levels are adversely affected in patients with dysglycaemia, and glucose normalization with insulin glargine might improve the levels of these factors. Methods: Prespecified Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial (ClinicalTrials.gov number, NCT00069784). Tissue plasminogen activator activity, tissue plasminogen activator antigen, plasminogen activator inhibitor-1 antigen, tissue plasminogen activator/plasminogen activator inhibitor-1 complex and von Willebrand factor were analysed at study start, after 2 years and at the end of the study (median follow-up of 6.2 years). Results: Of 129 patients (mean age of 64 ± 7 years, females: 19%), 68 (53%) and 61 (47%) were randomized to the insulin glargine and standard care group, respectively. Allocation to insulin glargine did not significantly affect the studied fibrinolytic markers or von Willebrand factor compared to standard care. Likewise, there were no significant differences in plasminogen activator inhibitor-1, tissue plasminogen activator antigen and von Willebrand factor. During the whole study period, the within-group analysis revealed a curvilinear pattern and significant changes for tissue plasminogen activator/plasminogen activator inhibitor-1 complex, tissue plasminogen activator antigen and von Willebrand factor in the insulin glargine but not in the standard care group. Conclusion: In people with dysglycaemia and other cardiovascular risk factors, basal insulin does not improve the levels of markers of fibrinolysis or von Willebrand factor compared to standard glucose-lowering treatments.
  •  
2.
  •  
3.
  •  
4.
  • Aidas, Kestutis, et al. (författare)
  • The Dalton quantum chemistry program system
  • 2014
  • Ingår i: ; 4:3, s. 269-284
  • Tidskriftsartikel (refereegranskat)abstract
    • Dalton is a powerful general-purpose program system for the study of molecular electronic structure at the Hartree-Fock, Kohn-Sham, multiconfigurational self-consistent-field, MOller-Plesset, configuration-interaction, and coupled-cluster levels of theory. Apart from the total energy, a wide variety of molecular properties may be calculated using these electronic-structure models. Molecular gradients and Hessians are available for geometry optimizations, molecular dynamics, and vibrational studies, whereas magnetic resonance and optical activity can be studied in a gauge-origin-invariant manner. Frequency-dependent molecular properties can be calculated using linear, quadratic, and cubic response theory. A large number of singlet and triplet perturbation operators are available for the study of one-, two-, and three-photon processes. Environmental effects may be included using various dielectric-medium and quantum-mechanics/molecular-mechanics models. Large molecules may be studied using linear-scaling and massively parallel algorithms. Dalton is distributed at no cost from for a number of UNIX platforms.
  •  
5.
  • Almroth, Henrik, et al. (författare)
  • Atorvastatin and persistent atrial fibrillation following cardioversion : a randomized placebo-controlled multicentre study
  • 2009
  • Ingår i: European Heart Journal. - Philadelphia : W.B. Saunders. - 0195-668X .- 1522-9645. ; 30:7, s. 827-833
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: To evaluate the effect of atorvastatin in achieving stable sinus rhythm (SR) 30 days after electrical cardioversion (CV) in patients with persistent atrial fibrillation (AF). METHODS AND RESULTS: The study included 234 patients. The patients were randomized to treatment with atorvastatin 80 mg daily (n = 118) or placebo (n = 116) in a prospective, double-blinded fashion. Treatment was initiated 14 days before CV and was continued 30 days after CV. The two groups were well-balanced with respect to baseline characteristics. Mean age was 65 +/- 10 years, 76% of the patients were male and 4% had ischaemic heart disease. Study medication was well-tolerated in all patients but one. Before primary endpoint 12 patients were excluded. In the atorvastatin group 99 patients (89%) converted to SR at electrical CV compared with 95 (86%) in the placebo group (P = 0.42). An intention-to-treat analysis with the available data, by randomization group, showed that 57 (51%) in the atorvastatin group and 47 (42%) in the placebo group were in SR 30 days after CV (OR 1.44, 95%CI 0.85-2.44, P = 0.18). CONCLUSION: Atorvastatin was not statistically superior to placebo with regards to maintaining SR 30 days after CV in patients with persistent AF.
  •  
6.
  • Andersson, Jonas, et al. (författare)
  • Markers of fibrinolysis as predictors for maintenance of sinus rhythm after electrical cardioversion
  • 2011
  • Ingår i: Thrombosis Research. - 0049-3848 .- 1879-2472. ; 127:3, s. 189-192
  • Tidskriftsartikel (refereegranskat)abstract
    • No fibrinolytic component alone was found to be a predictor of recurrence of atrial fibrillation. In multivariate models lower PAI-1 mass was associated with sinus rhythm even after adjusting for CRP, markers of the metabolic syndrome and treatment with atorvastatin. Our findings suggest a patophysiological link between AF and PAI-1 mass but the relation to inflammation remains unclear.
  •  
7.
  • Andersson, Jonas, et al. (författare)
  • NT-proBNP predicts maintenance of sinus rhythm after electrical cardioversion.
  • 2015
  • Ingår i: Thrombosis Research. - 0049-3848 .- 1879-2472. ; 135:2, s. 289-291
  • Tidskriftsartikel (refereegranskat)abstract
    • BACKGROUND: Atrial fibrillation (AF) is the most common arrhythmia. NT-proBNP is a fragment of the prohormone brain natriuretic peptide. Previous studies indicate that increased levels of NT-proBNP are associated with higher recurrence rates of AF after electrical cardioversion. Our null hypothesis was that NT-proBNP does not predict recurrence of AF after restoration of sinus rhythm.METHODS: We performed a hypothesis generating study within a double-blinded, placebo-controlled, randomized, prospective multicentre study of the effects of atorvastatin on recurrence of AF after electrical cardioversion. 199 patients with persistent AF and an indication for cardioversion were included in the present substudy. NT-proBNP was assessed prior to cardioversion. Cardioversion was performed according to local standard clinical practice on an elective outpatient basis. Patients were followed-up one month after cardioversion.RESULTS: 181 patients had a successful cardioversion and 91 of the study group remained in sinus rhythm at day 30. Recurrence of AF was observed in 108 patients at day 30. An optimal cutpoint for NT-proBNP at 500 ng/L predicted recurrence of AF after cardioversion (OR 2.94; 95% CI 1.30-6.63). In multivariate analysis adjusting for age, sex, hypertension, and treatment group strengthened the results (OR 3,56; 95% CI 1,44-8,81). When analysing the ROC curve of NT-proBNP in baseline and atrial fibrillation at day 30 the result was 0.57.CONCLUSION: NT-proBNP levels are a predictor of recurrence of AF 30 days after cardioversion. ROC curves indicates that the practical value of NT-proBNP for the individual patient is limited.
  •  
8.
  • Angerud, K. H., et al. (författare)
  • Areas for quality improvements in heart failure care: quality of care from the family members' perspective
  • 2018
  • Ingår i: Scandinavian Journal of Caring Sciences. - Hoboken : John Wiley & Sons. - 0283-9318 .- 1471-6712. ; 32:1, s. 346-353
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundThe complex needs of people with chronic heart failure (HF) place great demands on their family members, and it is important to ask family members about their perspectives on the quality of HF care. ObjectiveTo describe family members' perceptions of quality of HF care in an outpatient setting. MethodsA cross-sectional study using a short form of the Quality from Patients' Perspective (QPP) questionnaire for data collection. The items in the questionnaire measure four dimensions of quality, and each item consists of both the perceived reality of the care and its subjective importance. The study included 57 family members of patients with severe HF in NYHA class III-IV. ResultsFamily members reported areas for quality improvements in three out of four dimensions and in dimensionless items. The lowest level of perceived reality was reported for treatment for confusion and loss of appetite. Treatment for shortness of breath, access to the apparatus and access to equipment necessary for medical care were the items with the highest subjective importance for the family members. ConclusionFamily members identified important areas for quality improvement in the care for patients with HF in an outpatient setting. In particular, symptom alleviation, information to patients, patient participation and access to care were identified as areas for improvements. Thus, measuring quality from the family members' perspective with the QPP might be a useful additional perspective when it comes to the planning and implementation of changes in the organisation of HF care.
  •  
9.
  • Björck, Lena, 1959, et al. (författare)
  • Changes in Dietary Fat Intake and Projections for Coronary Heart Disease Mortality in Sweden: A Simulation Study
  • 2016
  • Ingår i: PloS one. - 1932-6203. ; 11:8
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: In Sweden, previous favourable trends in blood cholesterol levels have recently levelled off or even increased in some age groups since 2003, potentially reflecting changing fashions and attitudes towards dietary saturated fatty acids (SFA). We aimed to examine the potential effect of different SFA intake on future coronary heart disease (CHD) mortality in 2025. METHODS: We compared the effect on future CHD mortality of two different scenarios for fat intake a) daily SFA intake decreasing to 10 energy percent (E%), and b) daily SFA intake rising to 20 E%. We assumed that there would be moderate improvements in smoking (5%), salt intake (1g/day) and physical inactivity (5% decrease) to continue recent, positive trends. RESULTS: In the baseline scenario which assumed that recent mortality declines continue, approximately 5,975 CHD deaths might occur in year 2025. Anticipated improvements in smoking, dietary salt intake and physical activity, would result in some 380 (-6.4%) fewer deaths (235 in men and 145 in women). In combination with a mean SFA daily intake of 10 E%, a total of 810 (-14%) fewer deaths would occur in 2025 (535 in men and 275 in women). If the overall consumption of SFA rose to 20 E%, the expected mortality decline would be wiped out and approximately 20 (0.3%) additional deaths might occur. CONCLUSION: CHD mortality may increase as a result of unfavourable trends in diets rich in saturated fats resulting in increases in blood cholesterol levels. These could cancel out the favourable trends in salt intake, smoking and physical activity.
  •  
10.
  • Boman, Kurt, et al. (författare)
  • Effects of atenolol or losartan on fibrinolysis and von Willebrand factor in hypertensive patients with left ventricular hypertrophy.
  • 2010
  • Ingår i: Clinical and applied thrombosis/hemostasis. - 1076-0296 .- 1938-2723. ; 16:2, s. 146-152
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVES: To compare the effects of the beta-blocker atenolol with the angiotensin receptor blocker (ARB) losartan on plasma tissue-type plasminogen activator (tPA) activity and mass concentration, plasminogen activator inhibitor-1 (PAI-1) activity, tPA/PAI-1 complex, and von Willebrand factor (VWF). DESIGN: A prespecified, explorative substudy in 22 patients with hypertension and left ventricular hypertrophy (LVH) performed within randomized multicenter, double-blind prospective study. RESULTS: After a median of 36 weeks of treatment, there were significant differences between the treatment groups, atenolol versus losartan, in plasma median levels of tPA mass (11.9 vs 7.3 ng/mL, P = .019), PAI-1 activity (20.7 vs 4.8 IU/mL, P = .030), and tPA/PAI-1 complex (7.1 vs 2.5 ng/mL, P = .015). In patients treated with atenolol, median levels of tPA mass (8.9-11.9 ng/mL, P = .021) and VWF (113.5%-134.3%, P = .021) increased significantly, indicating a change toward a more prothrombotic state. No significant changes occurred in the losartan group. CONCLUSION: Losartan treatment was associated with preserved fibrinolytic balance compared to a more prothrombotic fibrinolytic and hemostatic state in the atenolol group. These findings suggest different fibrinolytic and hemostatic responses to treatment in hypertensive patients with LVH.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (207)
doktorsavhandling (11)
annan publikation (7)
konferensbidrag (5)
bokkapitel (1)
forskningsöversikt (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (192)
övrigt vetenskapligt (39)
populärvet., debatt m.m. (1)
Författare/redaktör
Boman, Kurt (222)
Wachtell, Kristian (55)
Boman, K. (48)
Gerdts, Eva (40)
Devereux, Richard B. (32)
Jansson, Jan Håkan (31)
visa fler...
Willenheimer, Ronnie (26)
Ray, Simon (25)
Olofsson, Mona (24)
Brännström, Margaret ... (22)
Nilsson, Torbjörn K (21)
Gohlke-Baerwolf, Chr ... (20)
Wachtell, K. (19)
Pedersen, Terje R. (19)
Egstrup, Kenneth (18)
Greve, Anders M. (17)
Nienaber, Christoph ... (16)
Johansson, Lars (15)
Dahlström, Ulf (15)
Bang, Casper N. (15)
Dahlöf, Björn (15)
Rossebo, Anne B. (14)
Gerdts, E. (14)
Nieminen, Markku S. (14)
Hallmans, Göran (13)
Devereux, R. B. (12)
Stalhammar, J (11)
de Simone, Giovanni (11)
Olsen, Michael H. (11)
Wikstrom, G. (10)
Kober, Lars (10)
Weinehall, Lars (10)
Okin, Peter M. (10)
Papademetriou, Vasil ... (10)
Holme, Ingar (9)
Lindmark, Krister (9)
Willenheimer, R. (9)
Gohlke-Bärwolf, Chri ... (9)
Nieminen, M. S. (9)
Stenlund, Hans (8)
Dahlöf, Björn, 1953 (8)
Olofsson, M. (8)
Kesäniemi, Y Antero (8)
Hagerman, Inger (8)
Nilsson, Torbjörn (7)
Alehagen, Urban (7)
Tornblom, M (7)
Hagerman, I (7)
Lindmark, K. (7)
Bergman, G. J. (7)
visa färre...
Lärosäte
Umeå universitet (207)
Lunds universitet (28)
Göteborgs universitet (23)
Uppsala universitet (18)
Linköpings universitet (9)
Karolinska Institutet (9)
visa fler...
Örebro universitet (8)
Kungliga Tekniska Högskolan (5)
Ersta Sköndal Bräcke högskola (4)
Linnéuniversitetet (3)
visa färre...
Språk
Engelska (208)
Svenska (23)
Odefinierat språk (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (162)
Naturvetenskap (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy